APSR2026-248

 
Late-Breaking
Submitted
Poster Presentation
 
AP16-002
P118
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1215918-46904-20261025b_434190.pdf
Format: PDF Only
15. Pulmonary Circulation
8

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Yuichi Nagata * Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Tetsutaro Nagaoka - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Honami Sugitani - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Yuriko Terayama - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Yoshifumi Suzuki - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Takashi Yoshida - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Sachiko Kuriyama - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
Kazuhisa Takahashi - Juntendo University Graduate School of Medicine Department of Respiratory Medicine Tokyo Japan
 
 
 
 
 
 
 
Presenting Author Details
Yuichi
Nagata
nagata.y.0802@gmail.com
+819093983803
31-40
Japan
Original Research
Clinical characteristics, severity, and prognosis of group 3 pulmonary hypertension with autoimmune features: validation using the Japan Pulmonary Hypertension Registry
Maximum 25 words
Abstract Content
Interstitial pneumonia with autoimmune features (IPAF) shows distinct clinical characteristics. However, the role of autoimmune features (AF) in group 3 pulmonary hypertension associated with chronic respiratory diseases (R-PH) is not well understood. We investigated whether AF affects pulmonary hemodynamics and prognosis in a nationwide registry.
We analyzed patients with group 3 R-PH registered in the Japanese Pulmonary Hypertension Registry (JAPHR). Patients with definite connective tissue disease were excluded. Based on the serological criteria of IPAF, patients were divided into AF and non-AF groups. We compared pulmonary hemodynamics, including mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR). Survival was analyzed using Kaplan–Meier curves and Cox proportional hazards models.
A total of 553 patients were included (IP 232, COPD 186, CPFE 85, others 50). 50 patients (9%) had AF (IP 27, COPD 9, CPFE 10, Others 4). In the overall R-PH cohort, the AF group had higher mPAP (35 vs. 29 mmHg, p<0.05) and higher PVR (5.2 vs. 3.7 Wood units, p<0.05) than the non-AF group. Similar results were observed in the IP subgroup (mPAP 32 vs. 27 mmHg p<0.05, PVR 5.0 vs. 3.5 Wood units p<0.05). In COPD and CPFE, the AF group also showed a trend toward higher mPAP and PVR. In survival analysis, AF patients in the IP and IP+CPFE groups tended to have better survival. In multivariable Cox analysis adjusted for major clinical variables, AF remained an independent predictor of prognosis (p<0.05).
In R-PH, AF was associated with more severe pulmonary hypertension but better survival, especially in IP and IP+CPFE. AF may define a distinct clinical phenotype in chronic lung disease–associated pulmonary hypertension.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Pulmonary Hypertension, Autoimmune Feature
maximum 3 keywords and no abbreviations, separated by commas
 
285